Cambridge academics honoured over the New Year
04 January 2016Members have been recognised for their outstanding contribution to society
Mitochondrial disease expert to lead Department of Clinical Neurosciences
23 July 2015Professor Patrick Chinnery, an expert in diseases that affect mitochondria – the ‘batteries’ that power our cells – has been appointed as Professor of Neurology and Head of the Department of Clinical Neurosciences at the University of Cambridge. He will take up his appointment on 1 October.
AstraZeneca and University of Cambridge strengthen long-standing partnership
16 October 2014AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.
NICE approves MS drug developed by University of Cambridge researchers
28 May 2014A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.
Researchers uncover 48 new genetic variants associated with multiple sclerosis
30 September 2013Brings to 110 known risk factors and provides important insight into disease mechanism.
Drug developed in Cambridge approved for treatment of multiple sclerosis
17 September 2013Approval concludes nearly 40-year epic journey from fundamental research to discovery of an effective treatment for active relapsing multiple sclerosis
New MS drug proves effective where others have failed
01 November 2012Alemtuzumab, a drug previously used to treat a type of leukaemia, shown to help people with early multiple sclerosis who relapsed on previous drugs as well as patients who had not yet been treated.
New treatment for multiple sclerosis: Cambridge University translates research at the bench into a drug at the bedside
14 November 2011Phase III clinical trials for new MS drug very positive.
Number of genes associated with MS doubles
11 August 2011Critical insight provided into the disease mechanisms behind multiple sclerosis.
Campath: from innovation to impact
01 August 2009The path from innovation to impact can be long and complex. Here we describe the 30-year journey behind the development of a drug now being used to treat multiple sclerosis.
